Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Verastem Inc. (VSTM:NASDAQ), powered by AI.
Verastem Inc. is currently trading at $5.80. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Verastem Inc. on Alpha Lenz.
Verastem Inc.'s P/E ratio is -1.9.
“Verastem Inc. trades at a P/E of -1.9 (undervalued) with modest ROE of -1480.2%. 3Y revenue CAGR of 128.4% highlights clear growth momentum.”
Ask for details →Verastem Inc. is a biopharmaceutical company that concentrates on developing and commercializing innovative cancer therapies. Its primary focus is on creating treatments targeting cancer cell survival and division pathways, specifically in hematologic malignancies and solid tumors. Key products in its pipeline include small molecule inhibitors that aim to disrupt cancer cell signaling and replication processes. Verastem Inc. plays a pivotal role within the healthcare and biotechnology sectors, contributing to advancements in precision medicine through its targeted therapies. Headquartered in Needham, Massachusetts, Verastem's research and development efforts are geared towards addressing unmet needs in oncology by providing new options for patients, thereby enhancing its importance in the biopharmaceutical market landscape. As it continues to make strides in cancer treatment, Verastem Inc. remains an integral player in the ongoing quest for more effective cancer solutions.
“Verastem Inc. trades at a P/E of -1.9 (undervalued) with modest ROE of -1480.2%. 3Y revenue CAGR of 128.4% highlights clear growth momentum.”
Ask for details →Verastem Inc. (ticker: VSTM) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 78 employees. Market cap is $402M.
The current price is $5.805 with a P/E ratio of -1.92x and P/B of 7.03x.
ROE is -1480.15% and operating margin is -550.33%. Annual revenue is $31M.